{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:06:19Z","timestamp":1789664779683,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"DOI":"10.7759\/cureus.28601","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T19:31:39Z","timestamp":1661887899000},"source":"Crossref","is-referenced-by-count":4,"title":["Clinical Approach to Nosocomial Bacterial Sepsis"],"prefix":"10.7759","author":[{"given":"Pramod","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.08.1460","article-title":"Culture negative severe sepsis: Nationwide trends and outcomes","volume":"150","author":"Gupta S","year":"2016","unstructured":"Gupta S, Sakhuja A, Kumar G, McGrath E, Nanchal RS, Kashani KB. Culture negative severe sepsis: Nationwide trends and outcomes. Chest. 2016, 150:1251-9. 10.1016\/j.chest.2016.08.1460","journal-title":"Chest"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer M","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al.. The Third International Consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016, 315:801-10. 10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0483OC","article-title":"Hospitalization type and subsequent severe sepsis","volume":"192","author":"Prescott HC","year":"2015","unstructured":"Prescott HC, Dickson RP, Rogers MA, Langa KM, Iwashyna TJ. Hospitalization type and subsequent severe sepsis. Am J Respir Crit Care Med. 2015, 192:581-8. 10.1164\/rccm.201503-0483OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin GS","year":"2003","unstructured":"Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003, 348:1546-54. 10.1056\/NEJMoa022139","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.0131","article-title":"Management of sepsis and septic shock","volume":"317","author":"Howell MD","year":"2017","unstructured":"Howell MD, Davis AM. Management of sepsis and septic shock. JAMA. 2017, 317:847-8. 10.1001\/jama.2017.0131","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay JP","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al.. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019, 200:e45-67. 10.1164\/rccm.201908-1581ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.01.022","article-title":"Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients","volume":"79","author":"Hess AS","year":"2014","unstructured":"Hess AS, Kleinberg M, Sorkin JD, et al.. Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients. Diagn Microbiol Infect Dis. 2014, 79:73-6. 10.1016\/j.diagmicrobio.2014.01.022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2020.1337","article-title":"Clinical consequences of contaminated blood cultures in adult hospitalized patients at an institution utilizing a rapid blood-culture identification system","volume":"42","author":"Liaquat S","year":"2021","unstructured":"Liaquat S, Baccaglini L, Haynatzki G, Medcalf SJ, Rupp ME. Clinical consequences of contaminated blood cultures in adult hospitalized patients at an institution utilizing a rapid blood-culture identification system. Infect Control Hosp Epidemiol. 2021, 42:978-84. 10.1017\/ice.2020.1337","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.07.017","article-title":"Antibiotic delays and feasibility of a 1-hour-from-triage antibiotic requirement: analysis of an emergency department sepsis quality improvement database","volume":"75","author":"Filbin MR","year":"2020","unstructured":"Filbin MR, Thorsen JE, Zachary TM, et al.. Antibiotic delays and feasibility of a 1-hour-from-triage antibiotic requirement: analysis of an emergency department sepsis quality improvement database. Ann Emerg Med. 2020, 75:93-9. 10.1016\/j.annemergmed.2019.07.017","journal-title":"Ann Emerg Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.015","article-title":"Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock","volume":"41","author":"Zelenitsky S","year":"2013","unstructured":"Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013, 41:255-60. 10.1016\/j.ijantimicag.2012.10.015","journal-title":"Int J Antimicrob Agents"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000513742","article-title":"Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review","volume":"52","author":"Blair M","year":"2021","unstructured":"Blair M, C\u00f4t\u00e9 JM, Cotter A, Lynch B, Redahan L, Murray PT.  Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review. Am J Nephrol. 2021, 52:85-97. 10.1159\/000513742","journal-title":"Am J Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000042","article-title":"Empiric antibiotic therapy of nosocomial bacterial infections","volume":"23","author":"Reddy P","year":"2016","unstructured":"Reddy P.  Empiric antibiotic therapy of nosocomial bacterial infections. Am J Ther. 2016, 23:e982-94. 10.1097\/MJT.0000000000000042","journal-title":"Am J Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000068","article-title":"Antimicrobials therapy of anaerobic infections","volume":"28","author":"Brook I","year":"2016","unstructured":"Brook I. Antimicrobials therapy of anaerobic infections. J Chemother. 2016, 28:143-50. 10.1179\/1973947815Y.0000000068","journal-title":"J Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of Carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann P","year":"2011","unstructured":"Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011, 17:1791-8. 10.3201\/eid1710.110655","journal-title":"Emerg Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.015","article-title":"Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review","volume":"55","author":"Mizrahi A","year":"2020","unstructured":"Mizrahi A, Delerue T, Morel H, Le Monnier A, Carbonnelle E, Pilmis B, Zahar JR. Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review. Int J Antimicrob Agents. 2020, 55:105834. 10.1016\/j.ijantimicag.2019.10.015","journal-title":"Int J Antimicrob Agents"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S183892","article-title":"Ceftriaxone-associated nephrolithiasis and gallstone in adults","volume":"10","author":"Azarkar G","year":"2018","unstructured":"Azarkar G, Birjand MM, Ehsanbakhsh A, Bijari B, Abedini MR, Ziaee M. Ceftriaxone-associated nephrolithiasis and gallstone in adults. Drug Healthc Patient Saf. 2018, 10:103-8. 10.2147\/DHPS.S183892","journal-title":"Drug Healthc Patient Saf"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13445","article-title":"Hemodialysis as a risk factor for ceftriaxone-associated pseudolithiasis in adults","volume":"24","author":"Ubukata M","year":"2020","unstructured":"Ubukata M, Ohsawa I, Suzuki H, et al.. Hemodialysis as a risk factor for ceftriaxone-associated pseudolithiasis in adults. Ther Apher Dial. 2020, 24:393-9. 10.1111\/1744-9987.13445","journal-title":"Ther Apher Dial"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx170","article-title":"Characterizing cefepime neurotoxicity: A systematic review","volume":"4","author":"Appa AA","year":"2017","unstructured":"Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS. Characterizing cefepime neurotoxicity: A systematic review. Open Forum Infect Dis. 2017, 4:ofx170. 10.1093\/ofid\/ofx170","journal-title":"Open Forum Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000000968","article-title":"New antimicrobial treatment options for severe Gram-negative infections","author":"Hetzler L","year":"2022","unstructured":"Hetzler L, Kollef MH, Yuenger V, Micek ST, Betthauser KD. New antimicrobial treatment options for severe Gram-negative infections. Curr Opin Crit Care. 2022, 10.1097\/MCC.0000000000000968","journal-title":"Curr Opin Crit Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8030122","article-title":"Present and future of carbapenem-resistant enterobacteriaceae (CRE) infections","volume":"8","author":"Suay-Garc\u00eda B","year":"2019","unstructured":"Suay-Garc\u00eda B, P\u00e9rez-Gracia MT. Present and future of carbapenem-resistant enterobacteriaceae (CRE) infections. Antibiotics (Basel). 2019, 8:10.3390\/antibiotics8030122","journal-title":"Antibiotics (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00010-19","article-title":"Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-\u03b2-lactamase-producing gram-negative bacteria","volume":"63","author":"Emeraud C","year":"2019","unstructured":"Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, Naas T, Dortet L. Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-\u03b2-lactamase-producing gram-negative bacteria. Antimicrob Agents Chemother. 2019, 63:10.1128\/AAC.00010-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.2020098","article-title":"Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia","volume":"20","author":"Bassetti M","year":"2022","unstructured":"Bassetti M, Melchio M, Giacobbe DR. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Rev Anti Infect Ther. 2022, 20:649-56. 10.1080\/14787210.2021.2020098","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a newly approved fluorocycline","volume":"38","author":"Lee YR","year":"2019","unstructured":"Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019, 38:1787-94. 10.1007\/s10096-019-03590-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161040-00008","article-title":"Linezolid: A review of its use in the management of serious gram-positive infections","volume":"61","author":"Perry CM","year":"2001","unstructured":"Perry CM, Jarvis B. Linezolid: A review of its use in the management of serious gram-positive infections. Drugs. 2001, 61:525-51. 10.2165\/00003495-200161040-00008","journal-title":"Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106310","article-title":"Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care","volume":"57","author":"Johnson TM","year":"2021","unstructured":"Johnson TM, Molina KC, Miller MA, Kiser TH, Huang M, Mueller SW. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Int J Antimicrob Agents. 2021, 57:106310. 10.1016\/j.ijantimicag.2021.106310","journal-title":"Int J Antimicrob Agents"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones TW","year":"2021","unstructured":"Jones TW, Jun AH, Michal JL, Olney WJ. High-dose daptomycin and clinical applications. Ann Pharmacother. 2021, 55:1363-78. 10.1177\/1060028021991943","journal-title":"Ann Pharmacother"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante KL","year":"2004","unstructured":"LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004, 48:4665-72. 10.1128\/AAC.48.12.4665-4672.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy123","article-title":"The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible staphylococcus aureus bacteremia","volume":"5","author":"Miller WR","year":"2018","unstructured":"Miller WR, Seas C, Carvajal LP, et al.. The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible staphylococcus aureus bacteremia. Open Forum Infect Dis. 2018, 5:ofy123. 10.1093\/ofid\/ofy123","journal-title":"Open Forum Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2017.05.011","article-title":"Evaluation and management of necrotizing soft tissue infections","volume":"31","author":"Bonne SL","year":"2017","unstructured":"Bonne SL, Kadri SS. Evaluation and management of necrotizing soft tissue infections. Infect Dis Clin North Am. 2017, 31:497-511. 10.1016\/j.idc.2017.05.011","journal-title":"Infect Dis Clin North Am"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab134","article-title":"Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study","volume":"76","author":"Babich T","year":"2021","unstructured":"Babich T, Naucler P, Valik JK, et al.. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study. J Antimicrob Chemother. 2021, 76:2172-81. 10.1093\/jac\/dkab134","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.09.002","article-title":"Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies","volume":"42","author":"Hu Y","year":"2013","unstructured":"Hu Y, Li L, Li W, Xu H, He P, Yan X, Dai H. Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: a meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents. 2013, 42:492-6. 10.1016\/j.ijantimicag.2013.09.002","journal-title":"Int J Antimicrob Agents"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab148","article-title":"Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series","volume":"3","author":"El-Dalati S","year":"2021","unstructured":"El-Dalati S, Sridaran S, Uricchio M, Kline EG, Shields R. Oxacillin plus ertapenem combination therapy leads to rapid blood culture clearance and positive outcomes among patients with persistent MSSA bacteraemia: a case series. JAC Antimicrob Resist. 2021, 3:dlab148. 10.1093\/jacamr\/dlab148","journal-title":"JAC Antimicrob Resist"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00425-19","article-title":"Comparable efficacy and better safety of double \u03b2-lactam combination therapy versus \u03b2\u2011lactam plus aminoglycoside in gram-negative bacteria in randomized, controlled trials","volume":"63","author":"Jiao Y","year":"2019","unstructured":"Jiao Y, Moya B, Chen MJ, et al.. Comparable efficacy and better safety of double \u03b2-lactam combination therapy versus \u03b2\u2011lactam plus aminoglycoside in gram-negative bacteria in randomized, controlled trials. Antimicrob Agents Chemother. 2019, 63:10.1128\/AAC.00425-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.14655","article-title":"Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial","volume":"316","author":"Timsit JF","year":"2016","unstructured":"Timsit JF, Azoulay E, Schwebel C, et al.. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, candida colonization, and multiple organ failure: the EMPIRICUS randomized clinical trial. JAMA. 2016, 316:1555-64. 10.1001\/jama.2016.14655","journal-title":"JAMA"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz408","article-title":"Early infectious disease consultation is associated with lower mortality in patients with severe sepsis or septic shock who complete the 3-hour sepsis treatment bundle","volume":"6","author":"Madaline T","year":"2019","unstructured":"Madaline T, Wadskier Montagne F, Eisenberg R, et al.. Early infectious disease consultation is associated with lower mortality in patients with severe sepsis or septic shock who complete the 3-hour sepsis treatment bundle. Open Forum Infect Dis. 2019, 6:ofz408. 10.1093\/ofid\/ofz408","journal-title":"Open Forum Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/107453-clinical-approach-to-nosocomial-bacterial-sepsis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:29Z","timestamp":1707508169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/107453-clinical-approach-to-nosocomial-bacterial-sepsis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.28601","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}